Navigation Links
T-beta-RIII joins the fight against breast cancer

Although the soluble factor TGF-beta has been shown to suppress the growth of tumor cells in the early stages of breast cancer, high levels of TGF-beta during the later stages of the disease are associated with a poor outcome. A study using human breast cancer samples and mice, which appears online on December 7 in advance of publication in the January print issue of the Journal of Clinical Investigation, indicates that changes in expression of one component of the TGF-beta receptor, T-beta-RIII, might provide a mechanism for the distinct effects of TGF-beta at the different stages of breast cancer.

Gerard Blobe and colleagues from Duke University showed that expression of T-beta-RIII by human breast cancer samples markedly decreased or was lost with disease progression. Conversely, in a mouse model of breast cancer, tumor cells engineered to express high levels of T-beta-RIII were less able to invade the breast tissue and to metastasize to other organs than tumor cells not engineered to express this protein. Further analysis revealed that the mechanism behind these protective effects of T-beta-RIII was likely to be T-beta-RIII cleavage at the cell membrane, which releases soluble T-beta-RIII that blocks TGF-beta signaling. As low levels of T-beta-RIII were found to be associated with decreased recurrence-free survival of patients with breast cancer and loss of T-beta-RIII was found to begin before tumors became invasive, the authors suggest that analysis of T-beta-RIII levels might help clinicians decide how aggressively to treat their patients.
'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. New Rotavirus vaccine joins routine infant immunization schedule
2. Learning to fight an adversary that wont stay down
3. Antibiotic might fight HIV-induced neurological problems
4. NYU study reveals how brains immune system fights viral encephalitis
5. Molecular models advance the fight against malaria
6. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
7. Researchers find promising cancer-fighting power of synthetic cell-signaling molecule
8. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
9. Two chemicals boost immune cells ability to fight HIV without gene therapy
10. Experiment station researchers to explore genome of disease-fighting fungus
11. Bacterial genome sheds light on synthesizing cancer-fighting compounds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... ... January 20, 2017 , ... ... the next evolution in spinal fusion, the MISquito Percutaneous Pedicle Screw System ... competition, SpineFrontier is focused on technique driven product solutions that provide maximum ...
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... development (R&D), today announced the launch of Data Science Services , ... rapidly evolving field of precision medicine. , Data Science Services allows ...
Breaking Biology Technology: